Literature DB >> 23356032

Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): reactions frequency in multibacillary patients.

Maria Lucia Fernandes Penna1, Samira Buhrer-Sékula, Maria Araci De Andrade Pontes, Rossilene Cruz, Heitor De Sá Gonçalves, Gerson Oliveira Penna.   

Abstract

SETTINGS: Many believe that the regular treatment for multibacillary (MB) leprosy cases could be shortened. A shorter treatment, allowing for uniform treatment for all cases, makes case classification superfluous and therefore simplifies leprosy control.
OBJECTIVE: To evaluate the association of the treatment duration with the frequency of reactions among MB patients.
METHODS: An open-label randomised clinical trial to compare the present routine treatment with one lasting six months. Patients were recruited between March 2007 and February 2012. We analysed the frequency of first reaction with the Kaplan-Meier method and of recurrent reaction with a Poisson regression, using the treatment group and baciloscopic index level (BI) as independent variables. Logistic regression was used to evaluate the statistical association of different reaction types and the treatment group.
RESULTS: Among those with BI < 3, we found a statistical significant difference of reaction frequencies between the treatment groups from 6 to 18 months since the beginning of treatment. This difference disappears at 2 years after the start of treatment. Multiple reactions were associated with the treatment group and with BI > or = 3. No specific types of reactions were associated with treatment duration.
CONCLUSION: Although this is the first report of U-MDT/CT-BR, the results presented here support the possibility of use of UMDT in the field.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23356032

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  14 in total

1.  Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Authors:  Rodrigo Scaliante Moura; Gerson Oliveira Penna; Ludimila Paula Vaz Cardoso; Maria Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Mariane Martins de Araújo Stefani; Samira Bührer-Sékula
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

2.  Global leprosy program: Does it need uniform-multi-drug therapy now?

Authors:  P Narasimha Rao; Sunil Dogra; Sujai Suneetha
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

3.  Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Authors:  Emerith Mayra Hungria; Regiane Morillas Oliveira; Gerson Oliveira Penna; Lúcio Cartaxo Aderaldo; Maria Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Ligia Regina Franco Sansigolo Kerr; Mariane Martins de Araújo Stefani; Samira Bührer-Sékula
Journal:  Infect Dis Poverty       Date:  2016-12-06       Impact factor: 4.520

Review 4.  Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

5.  Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Authors:  Gerson Oliveira Penna; Samira Bührer-Sékula; Lígia Regina Sansigolo Kerr; Mariane Martins de Araújo Stefani; Laura Cunha Rodrigues; Marcelo Grossi de Araújo; Andrea Machado Coelho Ramos; Ana Regina Coelho de Andrade; Maurício Barcelos Costa; Patricia Sammarco Rosa; Heitor de Sá Gonçalves; Rossilene Cruz; Maurício Lima Barreto; Maria Araci de Andrade Pontes; Maria Lúcia Fernandes Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

6.  Uniform multidrug therapy for leprosy - time for a rethink?

Authors:  Paul R Saunderson
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

7.  Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases.

Authors:  Mariane M A Stefani; Charlotte Avanzi; Samira Bührer-Sékula; Andrej Benjak; Chloé Loiseau; Pushpendra Singh; Maria A A Pontes; Heitor S Gonçalves; Emerith M Hungria; Philippe Busso; Jérémie Piton; Maria I S Silveira; Rossilene Cruz; Antônio Schetinni; Maurício B Costa; Marcos C L Virmond; Suzana M Diorio; Ida M F Dias-Baptista; Patricia S Rosa; Masanori Matsuoka; Maria L F Penna; Stewart T Cole; Gerson O Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-06-15

8.  Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).

Authors:  Emerith Mayra Hungria; Samira Bührer-Sékula; Regiane Morillas de Oliveira; Lúcio Cartaxo Aderaldo; Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Gerson Oliveira Penna; Mariane Martins de Araújo Stefani
Journal:  PLoS Negl Trop Dis       Date:  2017-02-21

9.  International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes.

Authors:  Ponnaiah Manickam; Sanjay M Mehendale; Bathyala Nagaraju; Kiran Katoch; Abdul Jamesh; Ramalingam Kutaiyan; Shen Jianping; Shivakumar Mugudalabetta; Vitthal Jadhav; Prabu Rajkumar; Jayasree Padma; Kanagasabai Kaliaperumal; Vijayakumar Pannikar; Padabettu Krishnamurthy; Mohan D Gupte
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

10.  Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.

Authors:  Emerith M Hungria; Samira Bührer-Sékula; Regiane M Oliveira; Lúcio C Aderaldo; Maria Araci A Pontes; Rossilene Cruz; Heitor S de Gonçalves; Maria L F Penna; Gerson O Penna; Mariane M A Stefani
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.